Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

    (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHIbWhRUUN3ME21Mlg3PjZizszN NVvHc5dYW0GQR1XS
DOHH-2 NYG0O|lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DKXGlEPTB;OT6zOVY5QSEQvF2= NG\UbHFUSU6JRWK=
no-10 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:yUYtHUUN3ME25MlkxOzlizszN M3eyZnNCVkeHUh?=
LS-513 NVHVW5M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mle0TWM2OD1zMT6zOVQ4KM7:TR?= MlGzV2FPT0WU
ALL-PO M2XDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7rW492UUN3ME2xNU44PzN2IN88US=> Mn7OV2FPT0WU
8-MG-BA MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\mUWlEPTB;MUOuNVEzOyEQvF2= NH;sT3JUSU6JRWK=
RPMI-8402 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;aO2lEPTB;MUWuPFU{PyEQvF2= MXLTRW5ITVJ?
EoL-1-cell MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jyWGlEPTB;MUiuOVk1QCEQvF2= NVnNOGRjW0GQR1XS
NALM-6 M2XuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTF7LkCxOlch|ryP MkLqV2FPT0WU
DEL NVS3UJZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJyLkG0O|Eh|ryP NH;SZ5dUSU6JRWK=
SR NVTZSVlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\uRmJsUUN3ME2yN{43PzF3IN88US=> MY\TRW5ITVJ?
697 NWDhWXpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXXTWM2OD1{Nj62NVU2KM7:TR?= M2\rT3NCVkeHUh?=
COLO-829 MkHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj6N3Y6UUN3ME2yOk45PDh|IN88US=> M2LrRnNCVkeHUh?=
EVSA-T NEDxNG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHzTWM2OD1{Nz61OVYyKM7:TR?= NGXkVYNUSU6JRWK=
ATN-1 M1Lo[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPPSHJKSzVyPUOxMlI{OjlizszN NVLIR5hQW0GQR1XS
L-363 M1fH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuwTWM2OD1|MT63OFYyKM7:TR?= NFL0NGNUSU6JRWK=
LAMA-84 M2fIOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPtTWM2OD1|Mj61NlEyKM7:TR?= M3i0dXNCVkeHUh?=
NOS-1 NV;3XpRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInWPW9KSzVyPUO0MlI6PTZizszN NWHod5BRW0GQR1XS
BB30-HNC NITycGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC5TWM2OD1|ND6zN|A3KM7:TR?= NG\OTGpUSU6JRWK=
BC-1 NIK2VHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHlfIl5UUN3ME2zO{46PzR4IN88US=> M2naVXNCVkeHUh?=
IST-SL2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfubVRpUUN3ME2zPE4zOjRizszN M1HuW3NCVkeHUh?=
D-392MG NVLhdJdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvpe4I{UUN3ME20NE4zOjF3IN88US=> NH3UVolUSU6JRWK=
no-11 M1fVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTRyLkW1NlEh|ryP NWLJVFF7W0GQR1XS
LC4-1 Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfTTmQ2UUN3ME20NE45PzF4IN88US=> NWrWRWlEW0GQR1XS
A388 NITK[GdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\XTWM2OD12Mj61PFQ5KM7:TR?= NXHweo1HW0GQR1XS
NTERA-S-cl-D1 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrDTWM2OD12Mj63NFc1KM7:TR?= NX3PWopzW0GQR1XS
CESS M3[4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj3TWM2OD12ND6yNlMzKM7:TR?= Mo\MV2FPT0WU
RS4-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVqzeZRbUUN3ME20PU4xQTN6IN88US=> MX;TRW5ITVJ?
MS-1 NYjNbG94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTVyLkmzOVEh|ryP NGXEOJBUSU6JRWK=
CTV-1 NVT3WVBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPFeldKSzVyPUWxMlA4PCEQvF2= MYnTRW5ITVJ?
D-502MG NV\WbGVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW1T3BKSzVyPUWxMlYzPzFizszN MorGV2FPT0WU
ML-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPTTWM2OD13Mj65NVk2KM7:TR?= M13oenNCVkeHUh?=
SK-NEP-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTV|LkO5NlMh|ryP NXjZUJJkW0GQR1XS
LOXIMVI MkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrFTWM2OD13Mz61PFg1KM7:TR?= MkHNV2FPT0WU
DJM-1 M{DGO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTV4LkOzPVEh|ryP Mm\xV2FPT0WU
GI-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH5XIp[UUN3ME21Ok43OTR7IN88US=> MVTTRW5ITVJ?
IST-MES1 M33yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTZyLkW0PVMh|ryP NH[3TZhUSU6JRWK=
MV-4-11 NIDRZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnUXYFKSzVyPU[wMlY2OzhizszN MXnTRW5ITVJ?
OVCAR-4 M4ThdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXm4fYo{UUN3ME22N{42PjV5IN88US=> MXvTRW5ITVJ?
KE-37 NUH5UpllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTZ4LkK2Olgh|ryP NGHNSYNUSU6JRWK=
D-542MG MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzob41KSzVyPU[4MlQyOzVizszN MoLhV2FPT0WU
MHH-PREB-1 M1G1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrue3BnUUN3ME23Nk45PDRzIN88US=> MkTCV2FPT0WU
MRK-nu-1 MmK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm5SXhyUUN3ME23N{41PzB3IN88US=> NFLXU2tUSU6JRWK=
D-247MG M2nJemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTETWM2OD15Mz61OFQzKM7:TR?= NF74d4JUSU6JRWK=
OCI-AML2 NVeyRVdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\JNI9KSzVyPUe2Mlk{PjlizszN NIK1Zm1USU6JRWK=
LP-1 M1\TSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDNe41lUUN3ME24Nk45PzNzIN88US=> MoLGV2FPT0WU
HCC1599 M{Lncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fVXGlEPTB;OESuNlg{PyEQvF2= M1jsVnNCVkeHUh?=
KARPAS-45 NWLybJU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTh2Lk[5PVIh|ryP NG\MSppUSU6JRWK=
BE-13 M3XN[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSzfWhxUUN3ME25PU4xPDd5IN88US=> MoDxV2FPT0WU
GCIY NVfUOZFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPCcmt5UUN3ME25PU4xQTV2IN88US=> NFryWoJUSU6JRWK=
BV-173 NX7DSmwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFyMD6zNlUh|ryP NIj5OoNUSU6JRWK=
LB2518-MEL Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS5RnhKSzVyPUGwNE44QDlizszN MVXTRW5ITVJ?
KS-1 MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFyMT62N|kh|ryP MkDCV2FPT0WU
MOLT-16 NXq0Oo1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPiTIhCUUN3ME2xNFQvQTh4IN88US=> MU\TRW5ITVJ?
NCI-H1770 NHvpfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFyOD63PFQh|ryP NGLmd45USU6JRWK=
NCI-H82 NHfXfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DRSGlEPTB;MUGwMlk4PiEQvF2= NWPKZXF{W0GQR1XS
NCCIT M2PNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH6ZW5KSzVyPUGxNk42OjlizszN NFTOcHNUSU6JRWK=
KALS-1 NVG2ZlYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DIZmlEPTB;MUG1Mlk1OSEQvF2= Mm\ZV2FPT0WU
LB2241-RCC Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPQdXQ5UUN3ME2xNVYvPjd7IN88US=> Mn24V2FPT0WU
HH MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFzNz6zPVUh|ryP M2TIOHNCVkeHUh?=
HD-MY-Z NYPSellDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X6NmlEPTB;MUG4MlQ5QCEQvF2= NUnmNm1JW0GQR1XS
EB-3 M2O3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjqWZBKSzVyPUGyN{4xQTRizszN Mn7vV2FPT0WU
BL-70 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF{Mz6xNlch|ryP NIrZRZpUSU6JRWK=
K-562 M4joTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7ETZVKSzVyPUGyOk4zPDVizszN MnHpV2FPT0WU
HT-144 NVTudo9PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXxXHBLUUN3ME2xN|MvOTZ2IN88US=> MX;TRW5ITVJ?
PF-382 M1rUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDPd3JTUUN3ME2xN|QvOzZzIN88US=> M1PvfnNCVkeHUh?=
RPMI-8226 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF|NT6wOFUh|ryP M4fNUnNCVkeHUh?=
NCI-H1355 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjaW5pZUUN3ME2xN|UvPTh5IN88US=> MUDTRW5ITVJ?
LXF-289 M3HYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;PNYJ4UUN3ME2xN|kvPzhzIN88US=> MUjTRW5ITVJ?
NCI-H69 M2TjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4G5eGlEPTB;MUSyMlk{OiEQvF2= M{jvfnNCVkeHUh?=
SK-MEL-1 MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUe5WXFpUUN3ME2xOFcvOTNizszN NHrQNmFUSU6JRWK=
KARPAS-299 MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF2OT6xNkDPxE1? M32wSnNCVkeHUh?=
GB-1 M1HNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLyVJo4UUN3ME2xOFkvOzJ{IN88US=> M4K2TXNCVkeHUh?=
CMK NXT2UYd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF2OT61NVUh|ryP NGPafGRUSU6JRWK=
MPP-89 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF3Nj6wN|Uh|ryP M4O4UXNCVkeHUh?=
KU812 Ml7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjN[mdKSzVyPUG2NU46ODJizszN MnjpV2FPT0WU
REH NUnN[|FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XBNWlEPTB;MU[yMlEzPSEQvF2= NVfic|lNW0GQR1XS
NEC8 NEHqRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7xTWM2OD1zNkWuNFI3KM7:TR?= NWrjdlZ5W0GQR1XS
KP-N-YS MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m5c2lEPTB;MU[4MlM6PSEQvF2= MnvJV2FPT0WU
Ramos-2G6-4C10 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M123eGlEPTB;MU[5MlkyPSEQvF2= NGjM[2VUSU6JRWK=
Becker MlHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjRb3pmUUN3ME2xO|QvOThizszN NFLRb3JUSU6JRWK=
LB647-SCLC NVr1VVR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTyVYVjUUN3ME2xO|UvQDR3IN88US=> NIC0OnJUSU6JRWK=
LU-139 MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{niNWlEPTB;MUe4MlAyQSEQvF2= Ml64V2FPT0WU
QIMR-WIL NIXlN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjCcJJKSzVyPUG3PU43PDZizszN M2L1b3NCVkeHUh?=
NCI-H1395 Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTF5OT65PVYh|ryP NH7zZ2pUSU6JRWK=
NOMO-1 M2jTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjSTWM2OD1zOEKuPFUh|ryP NWLwSXp2W0GQR1XS
GI-ME-N MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XUc2lEPTB;MUi3Mlk3QSEQvF2= MVnTRW5ITVJ?
KMS-12-PE M3XSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojBTWM2OD1zOEmuNlc{KM7:TR?= MV\TRW5ITVJ?
Daudi NFjB[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTyTWM2OD1zOUGuNVI5KM7:TR?= NGnsPWhUSU6JRWK=
LB996-RCC NF3EU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnX5TWM2OD1zOUGuOlk6KM7:TR?= MVHTRW5ITVJ?
NCI-H2107 Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPxTWM2OD1zOUOuO|M6KM7:TR?= MnTYV2FPT0WU
SK-PN-DW NFTQXVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGzTWM2OD1zOUSuO|E6KM7:TR?= M3rwUHNCVkeHUh?=
MC-CAR NGfHWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXjTWM2OD1{MEKuNlU{KM7:TR?= Mlu1V2FPT0WU
SNB75 NX[wU2ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHiTWM2OD1{MkGuPVQh|ryP NIfKTZlUSU6JRWK=
ES4 M1HUNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T6VmlEPTB;MkKzMlc5OyEQvF2= M3\VWXNCVkeHUh?=
KARPAS-422 M4PVWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDjTIpKSzVyPUKyPE4{PTJizszN MW\TRW5ITVJ?
NCI-H1648 Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nx[2lEPTB;MkK5MlQ5QSEQvF2= MkXEV2FPT0WU
ES6 MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PFZWlEPTB;MkO5MlQ{KM7:TR?= MoXoV2FPT0WU
KNS-81-FD MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TrNmlEPTB;MkSxMlE6PyEQvF2= MYPTRW5ITVJ?
JAR MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH0TWM2OD1{NU[uNlI2KM7:TR?= NWm1ZnF5W0GQR1XS
NB1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLqTWM2OD1{NkCuOVE3KM7:TR?= MWjTRW5ITVJ?
D-336MG M1H4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXYTWM2OD1{NkCuOlk5KM7:TR?= M1TYenNCVkeHUh?=
BC-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlmzTWM2OD1{NkWuNVc5KM7:TR?= MXHTRW5ITVJ?
HCC2218 Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmWzTWM2OD1{Nk[uOFE2KM7:TR?= NHrWbHZUSU6JRWK=
TE-9 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HsZ2lEPTB;Mk[2MlYzPyEQvF2= Mn\GV2FPT0WU
LB1047-RCC NYTUelVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDtTWM2OD1{Nk[uO|U{KM7:TR?= M2DHe3NCVkeHUh?=
CTB-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfrOYRKSzVyPUK2PU46PzNizszN M3vkV3NCVkeHUh?=
NB7 NGfMfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHrTWM2OD1{N{Gg{txO NXnufZBwW0GQR1XS
ST486 NFj4[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjpb3ZKSzVyPUK3O{41OTJizszN MmTTV2FPT0WU
HCC1187 NVvKZYFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf6fHU1UUN3ME2yPFIvQDFzIN88US=> MVfTRW5ITVJ?
NCI-SNU-16 NFjSSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zPVmlEPTB;Mki0MlI1QCEQvF2= MVPTRW5ITVJ?
COR-L279 NUHsWY9IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXFTWM2OD1{OUGuOVg1KM7:TR?= NXfUdFM5W0GQR1XS
ES8 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPXdHg4UUN3ME2yPVQvOTh{IN88US=> NX\xT5NTW0GQR1XS
U-698-M NUm5SGN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXLTWM2OD1{OUiuNlQ{KM7:TR?= M1HUfHNCVkeHUh?=
HEL MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvZZY5KSzVyPUOwPU4yPDlizszN NEO4ZndUSU6JRWK=
KINGS-1 MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2naTmlEPTB;M{GwMlY4PCEQvF2= MXHTRW5ITVJ?
KY821 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTN|Nj61PVUh|ryP NYDNWnpWW0GQR1XS
MZ1-PC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ftR2lEPTB;M{S1MlYyQCEQvF2= M3TZVnNCVkeHUh?=
LS-411N MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTN3ND62OkDPxE1? MoHDV2FPT0WU
SIG-M5 MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTN3OT63PFIh|ryP M4LCSHNCVkeHUh?=
HT M4riN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvMVWpKSzVyPUO2O{44OTFizszN MUPTRW5ITVJ?
HC-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTN4Nz63PFch|ryP MlPUV2FPT0WU
NCI-H1694 M{\DWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTN5Mj65N|Qh|ryP NHzkcXNUSU6JRWK=
BB65-RCC MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrYTWM2OD1|N{[uNlQ2KM7:TR?= NEnyVmFUSU6JRWK=
HAL-01 NWDFNIhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTN5OT64N|gh|ryP NV3BOJBUW0GQR1XS
ARH-77 MnT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD3TWM2OD1|OUSuNFA5KM7:TR?= MmL2V2FPT0WU
MZ7-mel NWS0bGp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfmWFlKSzVyPUO5O{4zOzNizszN M1HmPHNCVkeHUh?=
SIMA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTRyMz65N|Mh|ryP M3HSVHNCVkeHUh?=
DG-75 Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTRzNT62PVgh|ryP NG\PS4tUSU6JRWK=
HUTU-80 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjJTWM2OD12MUmuNVg2KM7:TR?= MlHkV2FPT0WU
KNS-42 NXXD[2tlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTR{NT64NVUh|ryP NGDt[oJUSU6JRWK=
SH-4 NIDWPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3vTWM2OD12MkeuOVY2KM7:TR?= MUPTRW5ITVJ?
L-540 NVfIVmNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPjS|hKSzVyPUSzNU4xOzFizszN M3PYNXNCVkeHUh?=
NB10 NV24dolrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzRTWM2OD12NEGuNlM1KM7:TR?= M2G1dXNCVkeHUh?=
ES1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDDNXFKSzVyPUS1Nk44PTNizszN NXXpUmtPW0GQR1XS
KMOE-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGToVZBKSzVyPUS1Ok44OTFizszN Mm\oV2FPT0WU
MC116 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTR3OD6xNVYh|ryP NYjJ[Xc5W0GQR1XS
RCC10RGB NUW0SYU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1WwcGlEPTB;NE[wMlAxPSEQvF2= MmH0V2FPT0WU
RL95-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLNTWM2OD12NkCuNlM4KM7:TR?= MmHZV2FPT0WU
Raji MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC5dVdKSzVyPUS2PE4yPDNizszN NF;O[|hUSU6JRWK=
CAS-1 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\tTWM2OD12N{KuNFc{KM7:TR?= MnLtV2FPT0WU
Calu-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTR5NT6yOlUh|ryP Mkf6V2FPT0WU
KG-1 NIrmSmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{juOGlEPTB;NEe4MlQ1KM7:TR?= MmHnV2FPT0WU
LB771-HNC MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTR6Mj6yN|Ih|ryP M2XGWnNCVkeHUh?=
ACN M12wZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP2UZRKSzVyPUS5N{42QTlizszN M2jiNnNCVkeHUh?=
KM12 NGX2W2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nWWGlEPTB;NEm2MlU5QSEQvF2= MkTrV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID